---
title: "Innovent Biologics Makes USD690 Million Structured Note Investments With JPMorgan and UBS"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287418100.md"
description: "Innovent Biologics has made USD690 million in structured note investments with JPMorgan and UBS, including JPM Notes I for USD280 million and UBS Notes for USD280 million. These transactions are structured as non-shareholder-approval under Hong Kong Listing Rules, highlighting their significance for the company's financial profile. The latest analyst rating for Innovent Biologics (HK:1801) is a Buy with a price target of HK$113.00."
datetime: "2026-05-22T15:12:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287418100.md)
  - [en](https://longbridge.com/en/news/287418100.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287418100.md)
---

# Innovent Biologics Makes USD690 Million Structured Note Investments With JPMorgan and UBS

### Meet Samuel – Your Personal Investing Prophet

-   Start a conversation with TipRanks’ trusted, data-backed investment intelligence
-   Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds

Innovent Biologics ( (HK:1801) ) just unveiled an update.

Innovent Biologics has entered into a series of investments in structured notes issued by J.P. Morgan Structured Products B.V. and UBS, totaling USD690 million in notional and principal amounts. These include the acquisition of JPM Notes I for USD280 million, JPM Notes II for USD130 million, and a subscription for UBS Notes of USD280 million, all structured as discloseable but non-shareholder-approval transactions under Hong Kong Listing Rules.

The JPM Notes I carry a maturity date of July 16, 2028, an implied simple yield of 4.65% per annum, and issuer call options with step-up redemption prices in 2026 and 2027, indicating Innovent’s use of yield-enhancing, callable instruments for treasury management. Aggregation of these transactions under the Listing Rules triggered disclosure obligations, underscoring the materiality of the company’s financial investments and their potential impact on its balance sheet and risk profile.

The most recent analyst rating on (HK:1801) stock is a Buy with a HK$113.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.

**More about Innovent Biologics**

Innovent Biologics, Inc. is a biopharmaceutical company focused on the research, development and commercialization of innovative medicines. Listed in Hong Kong, it operates in the healthcare sector and manages its capital through various financial instruments to support long-term growth and strategic initiatives.

**Average Trading Volume:** 12,195,606

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$138B

For a thorough assessment of 1801 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [01801.HK](https://longbridge.com/en/quote/01801.HK.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [UBS.US](https://longbridge.com/en/quote/UBS.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)

## Related News & Research

- [CICC Sticks to Their Buy Rating for Innovent Biologics (IVBXF)](https://longbridge.com/en/news/285050005.md)
- [This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%](https://longbridge.com/en/news/287440286.md)
- [Innovent Biologics (SEHK:1801): Reassessing Valuation After Landmark Nature Phase 3 Mazdutide Publications](https://longbridge.com/en/news/270320540.md)
- [Innovent Biologics (SEHK:1801): Reconciling a 116x P/E With DCF-Suggested Upside](https://longbridge.com/en/news/269231531.md)